ABSTRACT
A number of recent clinical investigations assessing the performance of the ABSORB bioresorbable vascular scaffold in large populations of patients with coronary artery disease have generated enthusiasm for the device as a promising therapeutic alternative to metallic drug-eluting stents (DESs). This chapter tabulates ongoing and completed investigator-driven randomized clinical trials assessing the effectiveness and safety of the bioresorbable scaffold. The Intracoronary Scaffold Assessment a Randomized Evaluation of ABSORB in Myocardial Infarction (ISAR-ABSORB MI) trial is a prospective, multi-center, noninferiority, randomized clinical trial comparing the performances of the everolimus-eluting bioresorbable scaffold and durable polymer metallic everolimus-eluting stent in the setting of acute myocardial infarction, both with and without scaffold thrombosis (ST)-elevation. The aim of the trial is to compare the short-term arterial healing response after bioresorbable scaffold and everolimus-eluting metallic stent implantation in coronary artery lesions with relevant thrombotic burden and a large necrotic core.
